Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) just unveiled an announcement.
Suzhou Basecare Medical Corp. Ltd. reported its interim financial results for the first half of 2025, showing a revenue decline to RMB 101,338,000 from RMB 124,739,000 in the same period of 2024. Despite the revenue drop, the company continues to innovate, having launched several advanced products in genetic testing, andrology diagnosis, and embryo culture, which are expected to enhance clinical outcomes and expand their market presence.
The most recent analyst rating on (HK:2170) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.
More about Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corp. Ltd. is an innovative medical device provider in China, specializing in assisted reproduction. The company offers a comprehensive range of products and services, including genetic testing, andrology diagnosis, cryopreservation, embryo culture, and intelligent management. Their mission is to facilitate access to high-quality reproductive technologies, aiming to become a leading global medical technology company.
Average Trading Volume: 506,261
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.06B
See more data about 2170 stock on TipRanks’ Stock Analysis page.